PRESENTATION

Q1 2025 — Results presentation

Q1 2025PDF · 32 pages8.2 MB
Slide footer goes here if required 	1

-- 1 of 32 --

1st Quarter 2025
Earnings Call
April 15, 2025

-- 2 of 32 --

Cautionary note on Forward-looking statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to
applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased
scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent
Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent
Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from
Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-
looking statement as a result of new information or future events or developments.
Cautionary note on Non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website.
3

-- 3 of 32 --

Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize
for a broad range of indications
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL
CONSTA developed in collaboration with Alkermes, Inc.
Infectious Diseases
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV
Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with
federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority
(BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S.
Department of Health and Human Services (HHS)
Cardiovascular/
Metabolism/Other
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration
with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals,
Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited;
AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from
Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs;
ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Pulmonary Hypertension 	UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan
Global Public Health
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo ® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Strategic partnerships, collaborations
& licensing arrangements
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:
4

-- 4 of 32 --

CEO Remarks
R&D highlights
Sales performance and earnings review
Capital allocation and guidance
Q&A
Agenda
1
2
3
4
5
5
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech

-- 5 of 32 --

Joaquin Duato
Chairman and Chief Executive Officer

-- 6 of 32 --

Innovative Medicine
4.2% 1,2 	Operational
sales growth
11 Key brands growing
double digits
Recent Milestones:
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of
the company's website. 2 Includes an approximate (810) basis point headwind from STELARA.

-- 7 of 32 --

`	`
MedTech
4.1% 1 	Operational
sales growth
Strong performance across
Abiomed, Shockwave, Vision
and Wound Closure
Recent Milestones:
Impella CP® with
SmartAssist®
Shockwave Javelin
Peripheral IVL
`
VARIPULSE
`
OTTAVA
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of
the company's website

-- 8 of 32 --

Fortifying our leadership as
an innovation powerhouse

-- 9 of 32 --



-- 10 of 32 --

John Reed
Executive Vice President,
Innovative Medicine, R&D

-- 11 of 32 --

12
CAPLYTA ®
Adjunctive treatment for major depressive disorder, has the potential to
become a new standard of care for most common depressive disorders
First and only U.S. FDA-approved
treatment for bipolar I and II
depression as an adjunctive and
monotherapy; also approved for the
treatment of schizophrenia in adults
Positive Phase 3 studies showed
meaningful MADRS score
improvements and reduced depression
severity with a favorable safety and
tolerability profile as an adjunctive
therapy
sNDA submitted to U.S. FDA for
adjunctive treatment for major
depressive disorder; expected
potential approval later this year
Study 501 (MADRS) 	Study 502 (MADRS)
Note: supplemental New Drug Application pending review by U.S. Food and Drug Administration
LS mean difference vs. placebo: -4.9 points
p < 0.0001
Cohen’s d effect size: 0.61
LS Mean Change from Baseline
Visit
***
***
****
****
**** ****
Baseline Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
-20
-15
-10
-5
-0 Placebo + ADT
Lumateperone 42mg + ADT
mITT population: Lumateperone N = 239, Placebo N = 242: ***p<0.001 ****p<0.0001
LS mean difference vs. placebo: -4.5 points
p < 0.0001
Cohen’s d effect size: 0.56
MADRS: Montgomery-Åsberg Depression Rating Scale (MADRS)
mITT population: Lumateperone N = 232, Placebo N = 237: *p<0.05 ****p<0.0001
LS mean difference vs. placebo: -4.5 points
p < 0.0001
Cohen’s d effect size: 0.56
LS Mean (+/- SE) Change from Baseline
Visit
*
****
****
**** ****
Baseline 	Week 1 	Week 2 Week 3 	Week 4 Week 5 	Week 6
-20
-15
-10
-5
-0 Placebo + ADT
Lumateperone 42mg + ADT
12

-- 12 of 32 --

Median OS
(95% CI)
Amivantamab +
lazertinib Not reached (42.9–NR)
Osimertinib 	36.7 mo (33.4–41.0)
HR, 0.75; (95% CI, 0.61–0.92); P<0.005 a
RYBREVANT® plus LAZCLUZE
First and only regimen with a survival benefit over current standard of
care in first-line treatment of EGFR-mutated non-small cell lung cancer
Significant and unprecedented
overall survival benefit vs standard
of care in Phase 3 MARIPOSA study
Changing the trajectory of survival,
with projected median OS
improvement of more than 1 year
Triple mechanism of action is
altering the natural history1 of this
type of lung cancer
1L RYBREVANT plus LAZCLUZE Overall Survival
Note: Last participant was enrolled in May 2022. Clinical cutoff date was December 4, 2024. In total, 390 deaths had occurred in the amivantamab + lazertinib (173 deaths) and osimertinib (217 deaths) arms.
aP-value was calculated from a log-rank test stratified by mutation type (Ex19del or L858R), race (Asian or Non-Asian), and history of brain metastasis (present or absent). Hazard ratio was calculated from a stratified Cox regression model.
+Yang J, et al. Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm) Advanced NSCLC: Final Overall Survival (OS)
from the Phase 3 MARIPOSA Study. 2025 European Lung Cancer Congress. March 26, 2025.
1 Besse B, et al. Presented at the European Society for Medical Oncology (ESMO) Congress; September 13-17, 2024; Barcelona, Spain.
*Based on an exponential distribution assumption of OS in both arms, the improvement in median OS is projected to exceed 1 year.
13

-- 13 of 32 --

14
TREMFYA®
Only dual-acting IL-23 inhibitor* for adult patients with
moderately to severely active Crohn’s disease
Structurally and functionally different
than other IL-23 inhibitors* – Potently
blocks IL-23 while also binding to CD64,
a receptor on cells that produce IL-23
Only IL-23i to show superiority versus
STELARA® in endoscopic endpoints in
Crohn’s disease (GALAXI 2/3) in a
registrational trial. First and only
biologic to achieve deep remission in
34% of patients at 1 year.3
Only IL-23 inhibitor with flexibility of
SC induction (GRAVITI), with results as
rapid and robust as IV
Overall population (Pooled GALAXI 2 & 3)1
* Based on in vitro studies in an inflammatory monocyte model. The clinical significance of these findings is unknown. "Only" based on approved selective
IL-23 inhibitors for moderately to severely active Crohn's disease as of March 2025
IV, intravenous; q4w, every 4 weeks; q8w, every 8 weeks; SC, subcutaneous.
1. Rubin DT, et al. American College of Gastroenterology 2024. Oral Presentation #OP73.
2.. Hart A, et al. Gastroenterology. Published online March 18, 2025; doi:10.1053/j.gastro.2025.02.033
3. Data not shown, 200mg q4w dose
TREMFYA® 200mg IV q4w 	100mg SC q8w
TREMFYA® 200mg IV q4w 	200mg SC q4w
STELARA® ~6mg/kg IV 	90mg SC q8w*
TREMFYA® 400mg SC q4w
PBO
GRAVITI - SC Induction 2
33% 37%
25%
0
20
40
60
Endoscopic Remission, Wk 48
137/286 	156/296 	108/291
Δ12.3%
P=0.001
Δ8.5%
P=0.024
Proportion of Patients (%)	
109/289
21%
56%
0
20
40
60
Proportion of Patients (%)	
25/117 	129/230
Δ35%
P<0.001
Clinical Remission, Wk 12
14

-- 14 of 32 --

15
icotrokinra
Demonstrating potential to transform
treatment paradigm in plaque psoriasis
Icotrokinra is the first targeted oral
peptide that selectively blocks the
IL-23R and shows potential to offer
patients the combination
of complete skin clearance and a
favorable safety profile in a once
daily pill
Nearly half of patients (46%)
achieved completely clear skin (IGA 0);
among adolescents this rate was 75%
These positive data build on the
comprehensive Ph3 ICONIC program,
which includes two H2H trials and the
ANTHEM Ph2 trial in ulcerative colitis
ICONIC-LEAD
1- Bissonette R. et al. Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3,
Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial. 2025 American Academy of Dermatology Association Annual Meeting. March 8, 2025.
2- Eichenfield, L., Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis. World Congress of Pediatric Dermatology; April 8-11, 2025, Buenos Aires,
Argentina
The data presented relates to an investigational product that is not yet approved by the FDA. It is for informational purposes only and should not be considered as a promotion or endorsement of the drug
***Multiplicity-adjusted P<0.001 vs PBO
ICO=icotrokinra, IGA=Investigator’s Global Assessment, PASI=Psoriasis Area and Severity Index, PASI 100=reduction from baseline of 100% in the PASI score, PBO=placebo.
Lesions graded based on induration, erythema and scaling and by body surface area over 4 body regions.
***
IGA 0 (total population) 1 IGA 0 (adolescents) 2
Proportion of participants
(95% CI)
Week
0
20
40
60
80
0 	2 	4 	8 	12 	16 	20 	24
40.9%
75%
40.9%
4.5%
PBO 	PBO to ICO 	ICO
0
20
40
60
0 	2 	4 	8 	12 	16 	20 	24
23%
1%
33%
46%
***
Proportion of participants
(95% CI)
Week
15

-- 15 of 32 --

Jessica Moore
Vice President,
Investor Relations

-- 16 of 32 --

Regional sales results 	Q1 2025 	Q1 2024
% Change
Reported 	Operational 1
U.S. 	$12.3 	$11.6 	5.9% 	5.9%
Europe 	5.1 	5.2 	(1.0) 	2.2
Western Hemisphere
(ex U.S.) 1.2 	1.2 	(2.3) 	9.2
Asia-Pacific, Africa 	3.3 	3.4 	(2.8) 	(0.6)
International 	9.6 	9.8 	(1.8) 	2.1
Worldwide (WW) 	$21.9 	$21.4 	2.4% 	4.2%
Dollars in billions
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Values may be rounded
1st Quarter 2025 sales
17

-- 17 of 32 --

$21.9 	$21.4
$6.7 	$6.6
2.2%; 3.7% 1
$2.77 	$2.71
Dollars in billions, except EPS
Reported %; Operational %1
Sales
Adjusted earnings2 	Adjusted EPS 2
2.4%; 4.2% 1
GAAP earnings
$11.0
$3.3
1.9%
Q1 2025 	Q1 2024
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
1st Quarter 2025 financial highlights
GAAP EPS
18
Q1 2025 	Q1 2024 	Q1 2025 	Q1 2024
Q1 2025 	Q1 2024 	Q1 2025 	Q1 2024
$4.54
$1.34
237.9% 	238.8%

-- 18 of 32 --

Immunology
$3,707	Infectious Diseases
$802
Neuroscience
$1,647
Oncology
$5,678 	CVM/Other
$1,013
PH
$1,025
■ Reported growth 	■ Operational growth1
$13,873
2.3%, 4.2%
WW sales $MM
Key drivers of operational performance 1
Oncology
• 	DARZALEX increase driven by continued strong share gains and market growth
• 	ERLEADA increase driven by continued share gains and market growth, partially offset by the
impact of Part D redesign
• 	CARVYKTI increase driven by continued share gains and capacity expansion
• 	TECVAYLI and TALVEY growth driven by ongoing launches
• 	RYBREVANT/LAZCLUZE growth driven by ongoing launch
• 	Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA due to competitive
pressures and the impact of Part D redesign
Immunology
• 	TREMFYA increase due to share gains and market growth, partially offset by the impact of Part
D redesign
• 	SIMPONI/SIMPONI ARIA growth driven mainly by MSD 3 return of rights in Europe
• 	REMICADE increase due to one-time favorable patient mix, market growth, and MSD3 return of
rights in Europe, partially offset by biosimilar competition
• 	STELARA decline driven by the impact of biosimilar competition and Part D redesign
Neuroscience
• 	SPRAVATO growth driven by ongoing launch and increased physician and patient demand
• 	INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA decline primarily driven by the
impact of Part D redesign
• 	Other Neuroscience decline primarily due to RISPERDAL/RISPERDAL CONSTA and PONVORY
divestiture
Pulmonary
Hypertension (PH)
• 	OPSUMIT/OPSYNVI growth driven by share gains and market growth, partially offset by the
impact of Part D redesign
• 	UPTRAVI decline driven by the impact of Part D redesign partially offset by market growth
Infectious Diseases 	• 	Declines across the portfolio including COVID-19 Vaccine, partially offset by EDURANT growth
Cardiovascular /
Metabolism / Other
(CVM/Other)
• 	XARELTO growth driven by one-time favorable patient mix and the impact of Part D redesign
Adjusted operational sales 2 : WW: 4.4%, U.S. 6.3%, Int’l 1.9%
Innovative Medicine highlights – 1st quarter 2025
Reported: 	WW 2.3%, U.S. 6.3%, Int’l (2.9)%
Operational 1: 	WW 4.2%, U.S. 6.3%, Int’l 1.5%
22.3%, 23.4%
(2.3)%, (1.2)%
17.9%, 20.4%
(2.2)%, 0.1%
(12.7)%, (10.9)%
Strong operational growth 1 of 4.2% driven primarily by Oncology
(8.6)%, (7.0)%
19
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 	3 MSD: Merck, Sharp, & Dohme
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website 	Note: Values may be rounded
Stelara impacted results 1 by ~(810) basis points

-- 19 of 32 --

Key drivers of operational performance 1
Cardiovascular
• 	Electrophysiology: Driven by competitive PFA pressures in ablation catheters and lapping of prior year inventory
build in Asia, mostly offset by global procedure growth, new product performance (NUVISION, VARIPULSE,
QDOT), and commercial execution
• 	Abiomed: Double digit growth driven by continued strong adoption of Impella 5.5 and Impella CP
• 	Shockwave: Acquired May 31, 2024
Orthopaedics
All platforms impacted by one-time events: the lapping of the prior year one-time revenue recognition timing
change related to certain products in the U.S., fewer selling days, and revenue disruption from the previously
announced Orthopaedics Transformation
• 	Hips: Reflects one-time events partially offset by continued portfolio strength (primarily in the Anterior approach)
• 	Trauma: Growth primarily driven by continued adoption of recently launched products, procedure growth, and
commercial execution, partially offset by one-time events
• 	Knees: Driven by one-time events and OUS tender timing partially offset by procedure growth, strength of the
ATTUNE portfolio (Cementless & Medial Stabilized), and pull through related to the VELYS Robotic assisted
solution
• 	Spine, Sports & Other: Reflects one-time events, competitive pressures, price pressures in the U.S. Early
Interventional segment, and volume-based procurement (VBP) in China, partially offset by growth in Shoulders
• 	Spine: ~ -13% WW, ~ -13% U.S., ~ -13% Int’l
Surgery
• 	Advanced
• 	Biosurgery: ~ +3% Growth driven by continued strength of the portfolio (SURGIFLO, SURGICEL Powder,
Evarrest, and VISTASEAL), commercial execution, and recovery from U.S. supply challenges, partially offset
by VBP
• 	Endocutters: ~ +2% Increase primarily due to commercial execution and strategic price actions, partially
offset by VBP
• 	Energy: ~ -3% Due to competitive pressures, Harmonic market decline in the U.S., and VBP, partially offset
by OUS tender timing and go to market changes in EMEA
• 	General: Growth primarily due to technology penetration and upgrades within our differentiated Wound Closure
portfolio (Barbed & PLUS Sutures) and OUS tender timing, partially offset by divestitures
Vision
• 	Contact Lenses/Other: Growth driven by price actions and continued strong performance of the ACUVUE
OASYS 1-Day family (including recent launch of OASYS MAX 1-Day)
• 	Surgical: Increase reflects continued strength of recent innovation (TECNIS Odyssey, TECNIS PureSee, TECNIS
Eyhance) and commercial execution, partially offset by competitive pressures in the U.S.
Adjusted operational sales 2 : WW 1.3%, U.S. 0.9%, Int’l 1.8%
Orthopaedics
$2,241
Surgery
$2,396
Vision
$1,279
Cardiovascular
$2,103
■ Reported growth 	■ Operational growth 1
$8,020
2.5%, 4.1%
WW sales $MM
Solid operational growth 1 of 4.1% due to Shockwave, commercial execution, and innovation
Reported: 	WW 2.5%, U.S. 5.1%, Int’l (0.2)%
Operational 1: 	WW 4.1%, U.S. 5.1%, Int’l 3.0%
16.4%, 17.7%
1.7%, 3.7%
(4.2)%, (3.1)%
(0.8)%, 1.1%
MedTech highlights – 1st quarter 2025
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website
3 One-time impacts include: the lapping of prior year Electrophysiology inventory dynamics in Asia and one-time revenue recognition timing change related to certain products in the U.S. in Orthopaedics, fewer selling days, and revenue disruption from the previously announced Orthopaedics Transformation
Note: Values may be rounded 	20
One-time 3 events impacted WW MedTech results 1 by ~(210) basis points, ~(240) in the U.S., and ~(180) Int’l

-- 20 of 32 --

One-time events include: lapping of a one-time revenue recognition timing change related to certain products across all
platforms in the U.S., fewer selling days, and revenue disruption from the previously announced Orthopaedics transformation
Approximate basis point impact of one-time events across all Orthopaedic platforms
Q1 2025 Operational 1 Growth
WW 	US 	OUS
Orthopaedics 	(3.1)% 	(4.4)% 	(0.9)%
Hips 	(1.9)% 	(2.5)% 	(0.8)%
Knees 	(1.7)% 	(4.3)% 	2.1%
Trauma 	2.1% 	(0.5)% 	7.2%
Spine/Sports/Other 	(9.7)% 	(10.2)% 	(8.9)%
Approximate basis point impact from one-time events
WW 	US 	OUS
(480) 	(650) 	(210)
(420) 	(590) 	(130)
(340) 	(510) 	(80)
(520) 	(730) 	(120)
(560) 	(680) 	(390)
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Orthopaedics one-time events

-- 21 of 32 --

2025 	2024 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$21,893 	100.0 	$21,383 	100.0 	2.4
Cost of products sold 	7,357 	33.6 	6,511 	30.4 	13.0
Gross Profit 	14,536 	66.4 	14,872 	69.6 	(2.3)
Selling, marketing and administrative expenses 	5,112 	23.3 	5,257 	24.6 	(2.8)
Research and development expense 	3,225 	14.7 	3,542 	16.6 	(8.9)
Interest (income) expense, net 	(128) 	(0.6) 	(209) 	(1.0)
Other (income) expense, net 	(7,321) 	(33.4) 	2,404 	11.2
Restructuring 	17 	0.1 	164 	0.8
Earnings before provision for taxes on income 	13,631 	62.3 	3,714 	17.4 	267.0
Provision for taxes on income 	2,632 	12.1 	459 	2.2 	473.4
Net Earnings 	$10,999 	50.2 	$3,255 	15.2 	237.9
-
Net earnings per share (Diluted) 	$4.54 	$1.34 	238.8
Average shares outstanding (Diluted) 	2,423.8 	2,430.1
Effective tax rate 	19.3% 	12.4%
.
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income 	$8,011 	36.6 	$7,877 	36.8 	1.7
Net earnings 	$6,706 	30.6 	$6,580 	30.8 	1.9
Net earnings per share (Diluted) 	$2.77 	$2.71 	2.2
Effective tax rate 	16.3% 	16.5%
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
(Unaudited; Dollar and shares in millions except per share figures)
22
1st Quarter 2025
Condensed consolidated statement of earnings

-- 22 of 32 --

Innovative Medicine 2025 	2024 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$13,873 	100.0 	$13,562 	100.0 	2.3
Cost of products sold 	3,371 	24.3 	2,670 	19.7 	26.3
Gross Profit 	$10,502 	75.7 	10,892 	80.3 	(3.5)
Selling, marketing and administrative expenses 	2,261 	16.3 	2,438 	18.0 	(7.3)
Research and development expense 	2,548 	18.4 	2,889 	21.3 	(11.8)
Other segment items 1 	(204) 	(1.5) 	(247) 	(1.9)
Adjusted segment income before tax 2 	$5,897 	42.5 	$5,812 	42.9 	1.5
1 Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website
(Unaudited; Dollar in millions)
Adjusted earnings before provision for taxes on income by segment
23
MedTech 2025 	2024 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$8,020 	100.0 	$7,821 	100.0 	2.5
Cost of products sold 	2,795 	34.8 	2,713 	34.7 	3.0
Gross Profit 	$5,225 	65.2 	5,108 	65.3 	2.3
Selling, marketing and administrative expenses 	2,656 	33.1 	2,578 	33.0 	3.0
Research and development expense 	671 	8.4 	601 	7.7 	11.6
Other segment items 1 	(182) 	(2.2) 	(132) 	(1.8)
Adjusted segment income before tax 2 	$2,080 	25.9 	$2,061 	26.4 	0.9
Enterprise 2025 	2024 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Adjusted segment income before tax 2 	$8,011 	36.6 	$7,877 	36.8 	1.7
1st Quarter 2025

-- 23 of 32 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 24 of 32 --

Capital allocation
Organic growth business needs
Free cash flow 2
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
Higher
priority
Lower
priority
Investment in M&A
Dollars in billions 	Q1 2025
Cash and marketable
securities 1 $38.8
Debt 	($52.3)
Net debt1 ($13.5)
Free cash flow2,3 ~$3.4
Q1 2025:
$3.2B invested in R&D
$3.0B in dividends paid
to shareholders
Note: Values may be rounded
1 Cash and net debt position impacted by ~$14.0 billion held cash in anticipation of Intra-Cellular Therapies acquisition in Q2. Pro-forma net debt position would be ~$27.5 billion
2 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment
3 Estimated as of April 15, 2025. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
4 Includes Intra-Cellular Therapies acquisition closed April 2, 2025 Note: Values may be rounded
Capital allocation strategy
25
~$14B 4 deployed in strategic,
inorganic growth opportunities

-- 25 of 32 --

Operational2 sales guidance of 3.8% and adjusted operational EPS 2,4 of 6.2% (midpoints)
April 2025 	January 2025 	Comments
Adjusted operational sales 1,2,6 	2.0% - 3.0% 	2.0% - 3.0% 	Maintaining
Operational sales 2,6 	$91.6B - $92.4B
3.3% - 4.3%
$90.9B - $91.7B
2.5% - 3.5%
Increasing midpoint by $0.7B to 3.8% due to
Intra-Cellular Therapies (ITCI) acquisition
Estimated reported sales 3,6 	$91.0B - $91.8B
2.6% - 3.6%
$89.2B - $90.0B
0.5% - 1.5%
Midpoint of $91.4B or 3.1%
Incremental FX impact of $1.1B or 1.3%
Adjusted pre-tax
operating margin4,5 	Increase of ~300 bps 	Increase of ~300 bps 	Maintaining
Net other income 4 	$1.0 - $1.2 billion 	$0.9 - $1.1 billion 	Increasing due to performance
Net interest expense / (income) 	$100 - $200 million 	$0 - ($100) million Decreasing due to ITCI financing costs
partially offset by performance
Effective tax rate 4 	16.5% - 17.0% 	16.5% - 17.0% 	Maintaining
Adjusted EPS (operational) 2,4 	$10.50 - $10.70
5.2% - 7.2%
$10.75 - $10.95
7.7% - 9.7%
Midpoint of $10.60 or 6.2%
$0.25 dilution from ITCI acquisition
Adjusted EPS (reported) 3,4 	$10.50 - $10.70
5.2% - 7.2%
$10.50 - $10.70
5.2% - 7.2%
Midpoint of $10.60 or 6.2%
Incremental FX impact of $0.25 or 2.5%
2025 P&L guidance
1 Non-GAAP measure; excludes acquisitions and divestitures 	4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 	5 Sales less: COGS, SM&A and R&D expenses
3 Euro Average Rate: April 2025 = $1.10; Euro Spot Rate: April 2025 = $1.11 	6 Excludes COVID-19 Vaccine
Note: Values may be rounded 	26

-- 26 of 32 --

Innovative
Medicine
• 	Expect more pronounced impact from newly launched products as the year progresses
• 	STELARA biosimilar competition to accelerate; HUMIRA erosion curve remains the best proxy 2
• 	Negative impact of Part D re-design, as a percent to sales, will be consistently applied throughout the year 3
• 	Expect acceleration of newly launched products; full benefit of Shockwave acquisition through May
• 	Lapping of prior year quarterly comparators to be considered
• 	Normalized procedure volume and seasonality
Phasing Considerations
MedTech
• 	One-time items impacting EPS last year:
• 	Benefit of Kenvue dividend in the first two quarters
• 	Higher interest income prior to Shockwave acquisition closure in May
• 	Monetization of royalty rights experienced in Q3
• 	IPR&D expense associated with NM-26 Bi-specific antibody acquisition (Q3) and V-Wave acquisition (Q4)
P&L
27
Anticipate second half operational1 sales growth higher than the first half
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Once faced with material biosimilar competition, with the additive impact of Part D re-design
3 Products negatively impacted include STELARA, INVEGA long acting injectables, ERLEADA, OPSUMIT, UPTRAVI, TREMFYA and IMBRUVICA, partially offset by a favorable impact in XARELTO

-- 27 of 32 --

Innovative Medicine
Anticipated 2025 milestones1 driving long-term value creation
MedTech
28
nipocalimab in gMG
RYBREVANT Sub-Q in NSCLC
TREMFYA Sub-Q in UC
TAR-200 NMIBC
icotrokinra in PsO and UC
RYBREVANT in HNC
CAPLYTA in aMDD
OTTAVA progression
Advancements across Cardiovascular
(incl. Electrophysiology, Heart
Recovery, and Circulatory
Restoration)
1 List above is not inclusive of all 2025 anticipated milestones
gMG: Generalized Myasthenia gravis; Sub-Q: Subcutaneous; NSCLC: Non-small cell lung cancer; UC: Ulcerative colitis; NMIBC: Non-muscle invasive bladder cancer; PsO: Psoriasis; HNC: head and neck cancer; aMDD: adjunctive major depressive disorder

-- 28 of 32 --

2027 / 2028 At-A-Glance
In-market brands
Current 2027 / 2028 market estimates
for specific product sales1,2
Our internal forecast vs. current
2027 /2028 market estimates 1,2
~$1.8B / ~$2.3B
~$2.1B / ~$2.3B
~$5.7B / ~$6.3B
2x higher
50% higher
25% higher
1 Market estimates based on analyst models as of April 9th, 2025 that identify product specific sales in 2027
2 Market estimates based on analyst models as of April 9th, 2025 that identify product specific sales in 2028
3 Previously referred to as TARIS platform
Potential sales of select Innovative Medicine assets vs. current market estimates 1
Pipeline
Current 2028 market estimates
for specific product sales 2
Our internal forecast vs.
current 2028 market estimates 2
Intravesical drug releasing system3 ~$0.7B
icotrokinra 	~$0.7B
3x higher
2x higher

-- 29 of 32 --

Q&A
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech

-- 30 of 32 --

Slide footer goes here if required 	31

-- 31 of 32 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA PRESENTATIONS¹
Phase III 	Phase I/ II
US SIMPONI (golimumab) 	US nipocalimab 	US nipocalimab 	 US
TAR-200 (RIS/gemcitabine plus
cetrelimab) 	AKEEGA (niraparib/abiraterone)
TAR-200 (RIS/gemcitabine plus
cetrelimab)
EU Pediatric Ulcerative Colitis
(PURSUIT 2)
EU Generalized Myasthenia Gravis
(Vivacity MG3)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
Non Muscle Invasive Bladder
Cancer (SunRISe-1)
M1 Metastatic Castration-
Sensitive Prostate Cancer
(AMPLITUDE)
Non Muscle Invasive Bladder Cancer
(SunRISe-1)
STELARA (ustekinumab) 	 US SPRAVATO (esketamine) 	TREMFYA (guselkumab) 	 RYBREVANT / LAZCLUZE 	RYBREVANT (amivantamab)
 EU Pediatric Crohn's Disease
(UNITI JR)
Treatment Resistant Depression
monotherapy (TRD4005)
 EU Ulcerative Colitis Subcutaneous
Induction (ASTRO)
Non Small Cell Lung Cancer
(MARIPOSA Final OS)
Head and Neck Cancer (ORIGAMI-4)
US TREMFYA (guselkumab) 	US CAPLYTA (lumateperone) 	US TREMFYA (guselkumab) 	 TREMFYA (guselkumab) 	TALVEY + TECVAYLI
Ulcerative Colitis Subcutaneous
Induction (ASTRO)
Adjunctive Treatment for Major
Depressive Disorder
Psoriatic Arthritis Structural
Damage (APEX)
Ulcerative Colitis Subcutaneous
Induction (ASTRO)
Multiple Myeloma
Relapsed/Refractory (RedirecTT-1)
 US TREMFYA (guselkumab) 	US DARZALEX (daratumumab) 	TREMFYA (guselkumab) 	TREMFYA (guselkumab) 	JNJ-4496
EU Crohn's Disease Subcutaneous
Induction (GRAVITI)
EU Smoldering Multiple Myeloma
(AQUILA)
 EU Pediatric Psoriasis
(PROTOSTAR)
Psoriatic Arthritis Structural
Damage (APEX)
Hematological Malignancies
(LYM1001)
US TREMFYA (guselkumab) 	US DARZALEX (daratumumab) 	US STELARA (ustekinumab) 	 TREMFYA (guselkumab) 	JNJ-5322
Pediatric Psoriasis
(PROTOSTAR)
 EU Frontline multiple myeloma
transplant ineligible (CEPHEUS)
EU Pediatric Ulcerative Colitis
(UNIFI JR)
Pediatric Psoriasis
(PROTOSTAR)
Multiple Myeloma (MMY1001)
US TREMFYA (guselkumab) 	US RYBREVANT (amivantamab) 	US STELARA (ustekinumab) 	 icotrokinra 	 RYBREVANT (amivantamab)
Pediatric Juvenile Psoriatic
Arthritis
 EU Subcutaneous (PALOMA-3) 	Pediatric Crohn's Disease
(UNITI JR)
Psoriasis (ICONIC-LEAD) 	Colorectal Cancer (ORIGAMI-1 right-
sided)
 US TREMFYA (guselkumab) 	IMBRUVICA (ibrutinib) 	US icotrokinra 	icotrokinra 	JNJ-8343
EU Crohn's Disease (GALAXI) 	EU Frontline MCL (Triangle) 	EU Psoriasis (ICONIC) 	Psoriasis (ICONIC-TOTAL) 	Prostate Cancer (PCR1001)
TREMFYA (guselkumab) 	icotrokinra 	JNJ-4804 Co-antibody Therapy
EU Ulcerative Colitis (QUASAR) 	Psoriasis (ICONIC-Advance1/2) 	Psoriatic Arthritis (AFFINITY)
aticaprant 	icotrokinra
Adjunctive Treatment for Major
Depressive Disorder with
Anhedonia (Ventura 1)
Ulcerative Colitis (ANTHEM)
RPGR Gene Therapy 	nipocalimab Combination Therapy
Retinitis Pigmentosa (LUMEOS) 	Rheumatoid Arthritis (DAISY)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2025*
1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and
assets and does not guarantee continued investment. This information is as of "&Date&" to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
1 In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets
and does not guarantee continued investments. This information is as of April 15, 2025 to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information.
= Achieved

-- 32 of 32 --